A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

被引：0

作者：

Hurvitz, S. A. ^{[1
]}

Galsky, M. D. ^{[2
]}

Shahidi, J. ^{[3
]}

Zhang, G. ^{[4
]}

Raza, S. ^{[3
]}

Necchi, A. ^{[5
]}

机构：

[1] UCLA Med Ctr, Dept Med, Los Angeles, CA USA

[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA

[3] Daiichi Sankyo Inc, Clin Dev, Basking Ridge, NJ USA

[4] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA

[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

370TiP

引用

页数：1

共 50 条

[41] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01) [J].

Krop, Ian E. ;

Saura, Cristina ;

Yamashita, Toshinari ;

Park, Yeon Hee ;

Kim, Sung-Bae ;

Tamura, Kenji ;

Andre, Fabrice ;

Iwata, Hiroji ;

Ito, Yoshinori ;

Tsurutani, Junji ;

Sohn, Joohyuk ;

Denduluri, Neelima ;

Perrin, Christophe ;

Aogi, Kenjiro ;

Tokunaga, Eriko ;

Im, Seock-Ah ;

Lee, Keun Seok ;

Hurvitz, Sara ;

Cortes, Javier ;

Lee, Caleb ;

Chen, Shuquan ;

Zhang, Lin ;

Shahidi, Javad ;

Yver, Antoine ;

Modi, Shanu .

CANCER RESEARCH, 2020, 80 (04)

[42] DS-8201a, a HER2-targeting antibody-drug conjugate, to elicit immune responses and benefits in combination with an anti-PD-1 antibody. [J].

Iwata, Tomomi Nakayama ;

Ishii, Chiaki ;

Ogitani, Yusuke ;

Wada, Teiji ;

Agatsuma, Toshinori .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[43] Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma [J].

Sheng, Xinan ;

Yan, Xieqiao ;

Wang, Lin ;

Shi, Yanxia ;

Yao, Xin ;

Luo, Hong ;

Shi, Benkang ;

Liu, Jiyan ;

He, Zhisong ;

Yu, Guohua ;

Ying, Jianming ;

Han, Weiqing ;

Hu, Changlu ;

Ling, Yun ;

Chi, Zhihong ;

Cui, Chuanliang ;

Si, Lu ;

Fang, Jianmin ;

Zhou, Aiping ;

Guo, Jun .

CLINICAL CANCER RESEARCH, 2021, 27 (01) :43-51

[44] A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation [J].

Lee, Elizabeth K. ;

Hendrickson, Andrea E. Wahner ;

Colon-Otero, Gerardo ;

Pickett, Cheryl A. ;

Xiong, Niya ;

Cheng, Su-Chun ;

Polak, Madeline ;

Sawyer, Hannah ;

Hayes, Martin ;

Matulonis, Ursula A. ;

Shapiro, Geoffrey I. ;

Konstantinopoulos, Panagiotis A. .

MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)

[45] POPULATION PHARMACOKINETIC ANALYSIS OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH HER2-POSITIVE BREAST CANCER OR OTHER SOLID TUMORS. [J].

Yin, O. ;

Xiong, Y. ;

Endo, S. ;

Yoshihara, K. ;

AbuTarif, M. ;

Wada, R. ;

LaCreta, F. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 :S48-S48

[46] A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer [J].

Planchard, D. ;

Li, B. T. ;

Murakami, H. ;

Shiga, R. ;

Lee, C. C. ;

Wang, K. ;

Janne, P. A. .

ANNALS OF ONCOLOGY, 2019, 30

[47] EXPOSURE-RESPONSE ANALYSES TO SUPPORT DOSE JUSTIFICATION OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN HER2-POSITIVE BREAST CANCER PATIENTS. [J].

Yin, O. ;

Wada, R. ;

Kastrissios, H. ;

AbuTarif, M. ;

Garimella, T. ;

Lee, C. ;

Zhang, L. ;

Shahidi, J. ;

LaCreta, F. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 :S41-S41

[48] EXPOSURE-RESPONSE ANALYSES TO SUPPORT DOSE JUSTIFICATION OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN HER2-POSITIVE BREAST CANCER PATIENTS. [J].

Yin, O. ;

Wada, R. ;

Kastrissios, H. ;

AbuTarif, M. ;

Garimella, T. ;

Lee, C. ;

Zhang, L. ;

Shahidi, J. ;

LaCreta, F. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 :S48-S48

[49] Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study [J].

Doi, Toshihiko ;

Shitara, Kohei ;

Naito, Yoichi ;

Shimomura, Akihiko ;

Fujiwara, Yasuhiro ;

Yonemori, Kan ;

Shimizu, Chikako ;

Shimoi, Tatsunori ;

Kuboki, Yasutoshi ;

Matsubara, Nobuaki ;

Kitano, Atsuko ;

Jikoh, Takahiro ;

Lee, Caleb ;

Fujisaki, Yoshihiko ;

Ogitani, Yusuke ;

Yver, Antoine ;

Tamura, Kenji .

LANCET ONCOLOGY, 2017, 18 (11) :1512-1522

[50] A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02) [J].

Meric-Bernstam, F. ;

Anoka, C. ;

Dobrowolska, A. ;

Chaudhry, A. ;

Rowbottom, J. ;

Gustavson, M. ;

Puvvada, S. .

ANNALS OF ONCOLOGY, 2021, 32 :S1253-S1254

← 1 2 3 4 5 →